PROPERTY, PLANT AND EQUIPMENT

Property and equipment consisted of the following:



(In thousands)	March 30, 2019			March 31, 2018
Land	$	7,337		$	7,450
Building and building improvements	118,821			114,646
Plant equipment and machinery	301,297			291,537
Office equipment and information technology	132,783			134,412
Haemonetics equipment	372,984			325,401
Total	933,222			873,446
Less: accumulated depreciation and amortization	(589,243		)	(541,290		)
Property, plant and equipment, net	$	343,979		$	332,156

Depreciation expense was $76.8 million, $57.7 million and $66.5 million in fiscal 2019, 2018 and 2017, respectively. There were no asset impairments included in depreciation expense during fiscal 2019. Fiscal 2018 and 2017 include $0.3 million and $10.0 million, respectively, of additional depreciation expense due to asset impairments.

As part of the acquisition of the whole blood business from Pall Corporation (“Pall”) in fiscal 2012, Pall agreed to manufacture and install in one of the Company's facilities a filter media manufacturing line (the “HDC line”) for which the Company agreed to pay Pall approximately $15.0 million (plus pre-approved overages). Pall also agreed to supply media to the Company for use in leukoreduction filters until such time as the Company accepted the HDC line.

In May 2018, the Company entered into a long-term supply agreement with Pall under which Pall will continue to supply media to the Company for use in leukoreduction filters. As a condition of the supply agreement, the Company agreed to accept the HDC line and to make a final payment of $9.0 million to Pall for the HDC line.

As a result of the decision to continue to source media for leukoreduction filters from Pall rather than producing them internally, the Company does not expect to utilize the HDC line for future production and expects that the asset’s future cash flows will not be sufficient to recover its carrying value of $19.8 million. Accordingly, during the first quarter of fiscal 2019 the Company recorded impairment charges of $19.8 million for the HDC line.

During fiscal 2019, the Company impaired an additional $1.4 million of property, plant and equipment as a result of the Company's review of non-core and underperforming assets, resulting in total impairment charges of $21.2 million during fiscal 2019. These impairments were included within cost of goods sold on the consolidated statements of income (loss) and impacted the All Other reporting segment. During fiscal 2018 and 2017, the Company impaired $2.2 million and $13.3 million of property, plant and equipment, respectively.

Additionally, the Company has changed the estimated useful lives of PCS^®2 devices, included within Haemonetics Equipment, as these will be replaced by the NexSys PCS^®which the Company began placing during the second quarter of fiscal 2019. During fiscal 2019, the Company incurred $18.0 million of accelerated depreciation expense related to this change in estimate.